66647-17-4

Basic information

• Product Name: (2R,3R)-Diethyl-2,3-epoxysuccinate
• CAS NO: 66647-17-4
• Molecular Weight: 188.18
• Mol File: 66647-17-4.mol

Chemical Properties

• CAS DataBase Reference: (2R,3R)-Diethyl-2,3-epoxysuccinate(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3R)-Diethyl-2,3-epoxysuccinate(66647-17-4)
• EPA Substance Registry System: (2R,3R)-Diethyl-2,3-epoxysuccinate(66647-17-4)

Safety Data

• Hazardous Substances Data: 66647-17-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2R,3R)-Diethyl-2,3-epoxysuccinate is used as a reagent for the formation of heterocyclic compounds and as a precursor for the synthesis of various pharmaceuticals and agrochemicals. Its unique epoxide functional group and chiral centers enable the creation of a wide range of complex molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
(2R,3R)-Diethyl-2,3-epoxysuccinate is used as a starting material for the development of new drugs and biologically active compounds. Its potential biological activities have been studied, and it can be utilized in the discovery and synthesis of novel therapeutic agents.
Used in Agrochemical Industry:
(2R,3R)-Diethyl-2,3-epoxysuccinate is used as a precursor in the synthesis of agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural chemicals to improve crop protection and yield.

Upstream product

• 188944-76-5 2-Bromo-3-hydroxy-succinic acid diethyl ester 
• 623-91-6 diethyl Fumarate 
• 64-17-5 ethanol 
• 17087-75-1 (-)-trans-2,3-oxiranedicarboxylic acid 
• 93713-32-7 (+)-(2S,3S)-trans-Oxiran-2,3-dicarbonsaeure-L-Arginin-Salz 
• 141-36-6 DL-trans-epoxysuccinic acid 
• 57968-71-5 (+/-)-diethyl tartrate 
• 13811-71-7 diethyl (2S,3S)-tartrate 
• 80640-15-9 diethyl (2S,3R)-(+)-erythro-2-hydroxy-3-bromosuccinate 
• 691-84-9 Diethyl (S)-malate 
• 1520-50-9 but-2-enedioic acid diethyl ester 

Downstream Products

• 141-36-6 DL-trans-epoxysuccinic acid 
• 63734-73-6 ethyl (2S,3S)-3-carboxylate oxirane-2-carboxylic acid 
• 1448429-23-9 (2S,3S)-ethyl-3-((S)-1-oxo-1-((1-(4-sulfamoylphenyl)-1H-1,2,3-triazol-4-yl)methylamino)-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-24-0 (2S,3S)-ethyl-3-((S)-1-((1-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-25-1 (2S,3S)-ethyl-3-((S)-1-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-26-2 (2S,3S)-ethyl-3-((S)-1-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-27-3 (2S,3S)-ethyl-3-((S)-1-((1-(2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-28-4 (2S,3S)-ethyl-3-((S)-1-((1-mesityl-1H-1,2,3-triazol-4-yl)methylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-30-8 (2S,3S)-ethyl 3-((S)-4-methyl-1-oxo-1-(phenylamino)pentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-31-9 (2S,3S)-ethyl 3-((S)-1-(2,6-difluorophenylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-33-1 (2S,3S)-ethyl 3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-35-3 (2S,3S)-ethyl 3-((S)-1-(4-(4-fluorophenylsulfonamido)butylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-38-6 (2S,3S)-ethyl 3-((S)-3-(1H-imidazol-5-yl)-1-oxo-1-(phenylamino)propan-2-ylcarbamoyl)oxirane-2-carboxylate 
• 1448429-39-7 (2S,3S)-ethyl 3-((S)-3-(1H-imidazol-5-yl)-1-(mesitylamino)-1-oxopropan-2-ylcarbamoyl)oxirane-2-carboxylate 

Relevant articles and documents

Stereoselective synthesis of optically active forms of δ-multistriatin, the attractant for european populations of the smaller european elm bark beet

A stereoselective synthesis of highly optically pure enantiomers of δ-multistriatin [(1S,2S,4S,5R)-2,4-dimethyl-5-ethyl-6, 8-dioxabicyclo[3.2.1)octane and its antipode] was accomplished starting from tartaric acid enantiomers.

Benchtop-Stabssle Hypervalent Bromine(III) Compounds: Versatile Strategy and Platform for Air- And Moisture-Stable λ3-Bromanes

We present the first synthesis of air/moisture-stable λ3-bromanes (9and10) by using a cyclic 1,2-benzbromoxol-3-one (BBX) strategy. X-ray crystallography and NMR and IR spectroscopy ofN-triflylimino-λ3-bromane (12) revealed that the bromine(III) center is effectively stabilized by intramolecular R-Br-O hypervalent bonding. This strategy enables the synthesis of a variety of air-, moisture-, and benchtop-stable Br-hydroxy, -acetoxy, -alkynyl, -aryl, and bis[(trifluoromethyl)sulfonyl]methylide λ3-bromane derivatives.

2,3-EPOXY SUCCINYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or

Approaching an experimental electron density model of the biologically active trans-epoxysuccinyl amide group—Substituent effects vs. crystal packing

The trans-epoxysuccinyl amide group as a biologically active moiety in cysteine protease inhibitors such as loxistatin acid E64c has been used as a benchmark system for theoretical studies of environmental effects on the electron density of small active i

Design, synthesis, and structure–activity relationship study of epoxysuccinyl–peptide derivatives as cathepsin B inhibitors

Cathepsin B is a lysosomal cysteine protease involved in many diseases. The present research demonstrates that derivatives of epoxysuccinyl–peptide are effective and selective cathepsin B inhibitors. We synthesized a series of epoxysuccinyl–peptide deriva

Cysteine protease inhibitors and uses thereof

The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine

2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof

Provided are a compound of formula I which can be used as a drug against small RNA virus infections, and optical isomers, pharmaceutically acceptable salts, solvates or hydrates thereof. Also provided are the preparation method of the compound, the method for using the compound for treating bacterial infections and the use of the compound in the preparation of a drug for preventing and/or treating viral diseases caused by small RNA viruses.

Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors

Hyperactivation of the calcium-dependent cysteine protease calpain 1 (Cal1) is implicated as a primary or secondary pathological event in a wide range of illnesses and in neurodegenerative states, including Alzheimer's disease (AD). E-64 is an epoxide-containing natural product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal models of AD. By use of E-64 as a lead, three successive generations of calpain inhibitors were developed using computationally assisted design to increase selectivity for Cal1. First generation analogues were potent inhibitors, effecting covalent modification of recombinant Cal1 catalytic domain (Cal1cat), demonstrated using LC-MS/MS. Refinement yielded second generation inhibitors with improved selectivity. Further library expansion and ligand refinement gave three Cal1 inhibitors, one of which was designed as an activity-based protein profiling probe. These were determined to be irreversible and selective inhibitors by kinetics studies comparing full length Cal1 with the general cysteine protease papain.

Design, synthesis, and screen of cathepsin K inhibitors

We synthesized a series of epoxysuccinic acid derivatives and evaluated their in vitro cathepsin K inhibitory activity The screening results show that the potency of compounds 9e, 9d, 9p, 9j and 9k (IC50 ≤ 0.005 μmol/L) were equal to or greater than that of the lead compound 9a. Less hydrophobic compounds showed weaker potency, which can be explained by the hydrophobic nature of the cathepsin K binding pockets.

Two-step labeling of endogenous enzymatic activities by Diels-Alder ligation

A ligation strategy based on the Diels-Alder [4+2] cycloaddition for the two-step activity-based labeling of endogenously expressed enzymes in complex biological samples has been developed. A panel of four diene-derivatized proteasome probes was synthesized, along with a dienophile-functionalized BODIPY(TMR) tag. These probes were applied in a Diels-Alder labeling procedure that enabled us to label active proteasome β-subunits selectively in cellular extracts and in living cells. We were also able to label the activity of cysteine proteases in cell extracts by utilizing a diene-derivatized cathepsin probe. Importantly, the Diels-Alder strategy described here is fully orthogonal with respect to the Staudinger-Bertozzi ligation, as demonstrated by the independent labeling of different proteolytic activities by the two methods in a single experiment.